Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.88
Nov 19 • 3:59 PM ET Dollar change-0.01 Percentage change(-0.53%)
Aftermarket Close
1.77
Aftermarket • 5:49 PM ET Dollar change-0.11 Percentage change(-5.85%)
Index
-
Market Cap
3.98M
Enterprise Value
-4.38M
Income
-3.72M
Sales
0.04M
Book/sh
4.48
Cash/sh
3.95
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
3
IPO
May 13, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
99.50
P/B
0.42
P/C
0.48
P/FCF
-
EV/EBITDA
-
EV/Sales
-109.50
Quick Ratio
24.43
Current Ratio
24.43
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-3.76
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
33.45% 26.52%
Sales past 3/5Y
0.00% -
EPS Y/Y TTM
72.96%
Sales Y/Y TTM
-50.00%
EPS Q/Q
88.49%
Sales Q/Q
-100.00%
Earnings
-
EPS/Sales Surpr.
- -
Insider Own
9.75%
Insider Trans
0.00%
Inst Own
14.13%
Inst Trans
0.63%
ROA
-49.01%
ROE
-55.30%
ROIC
-44.05%
Gross Margin
-1356.72%
Oper. Margin
-12534.05%
Profit Margin
-10319.04%
SMA20
25.51%
SMA50
23.44%
SMA200
-56.33%
Trades
Shs Outstand
2.12M
Shs Float
1.91M
52W High
10.43 -81.97%
52W Low
1.10 70.91%
Volatility
15.74% 11.36%
ATR (14)
0.19
RSI (14)
62.43
Beta
0.59
Rel Volume
1.44
Avg Volume
65.62K
Volume
97,357
Perf Week
-1.57%
Perf Month
56.67%
Perf Quarter
-29.06%
Perf Half Y
-66.67%
Perf YTD
-63.14%
Perf Year
-68.27%
Perf 3Y
-92.10%
Perf 5Y
-98.71%
Perf 10Y
-99.54%
Prev Close
1.89
Price
1.88
Change %
-0.53%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weisblum EricChief Executive OfficerDec 15 '25Buy0.415,0002,075216,932Dec 16 06:34 PM
Weisblum EricChief Executive OfficerNov 21 '25Buy0.361,000365211,932Nov 21 06:35 PM
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.
ChairmanMr. Eric Weisblum
Chief Financial OfficerMr. Daniel E. Ryweck